Skip NavigationSkip to Content

Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro

  1. Author:
    Ciolino, H. P.
    MacDonald, C. J.
    Memon, O. S.
    Bass, S. E.
    Yeh, G. C.
  2. Author Address

    NCI, Cellular Def & Carcinogenesis Sect, Lab Metab, Ctr Canc Res,NIH, Frederick, MD 21701 USA. NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21701 USA.;Ciolino, HP, NCI, Cellular Def & Carcinogenesis Sect, Lab Metab, Ctr Canc Res,NIH, Frederick, MD 21701 USA.;hcp@mail.utexas.edu
    1. Year: 2006
    2. Date: Aug
  1. Journal: Carcinogenesis
    1. 27
    2. 8
    3. Pages: 1586-1592
  2. Type of Article: Article
  3. ISSN: 0143-3334
  1. Abstract:

    Sulindac, a widely used non-steroidal anti-inflammatory drug (NSAID), has been shown to inhibit chemically induced carcinogenesis in animal models. In the present study, we have investigated the molecular mechanism by which sulindac affects the activity and expression of the enzymes that mediate the initial detoxification steps of many environmental carcinogens, the cytochromes P450 1A1, 1A2 and 1B1. Sulindac treatment of Sprague-Dawley rats resulted in a dose-dependent increase in hepatic cytochrome P450 (CYP) enzyme activity and in the expression of hepatic CYPs 1A1 and 1B1 mRNA. In the HepG2 human liver cancer cell line, sulindac caused a sustained, dose-dependent increase in CYP enzyme activity. Sulindac treatment resulted in a profound, dose-dependent increase in CYP 1A1 mRNA and a modest increase in 1A2 mRNA. The increase in CYP 1A1 mRNA induced by sulindac was, like enzyme activity, sustained for several days after the initial treatment. Sulindac induced the transcription of the CYP1A1 gene, as measured by the level of heterogeneous nuclear 1A1 RNA and by actinomycin D chase experiment. Since the transcription of CYP1A1 is under the control of the aryl hydrocarbon receptor (AhR), we examined the ability of sulindac to activate the receptor. Sulindac bound to the AhR, as measured by ligand-binding assay, and induced the binding of the AhR with the xenobiotic-responsive element present in the promoter region of the CYP1A1 gene. These results are the first demonstration that NSAIDs modulate carcinogen metabolic enzymes and provide a novel mechanism to explain the established chemopreventive activity of sulindac.

    See More

External Sources

  1. DOI: 10.1093/carcin/bgi359
  2. WOS: 000239841100008

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel